Erythropoietin, Serum
Use
This test is useful in aiding the differentiation between primary and secondary polycythemia. It helps in distinguishing between appropriate secondary polycythemia (caused by conditions such as high-altitude living, pulmonary disease, or tobacco use) and inappropriate secondary polycythemia (such as those caused by tumors). It is also useful in identifying candidates for erythropoietin (EPO) replacement therapy, such as those with chronic kidney disease, and evaluating patients undergoing EPO therapy who exhibit an inadequate hematopoietic response.
Special Instructions
Not provided.
Limitations
Erythropoietin (EPO) levels alone cannot reliably distinguish between primary and secondary polycythemia, as EPO levels may be within normal limits in some patients with primary polycythemia. Assays may differ significantly among commercial EPO tests, and it's recommended to use the same test for serial assessments. The presence of heterophile antibodies can interfere with this assay, and discrepancies in results should prompt further investigation. The assay cannot distinguish between endogenous and exogenous EPO, nor can it measure recombinant EPO compounds accurately; their levels can be estimated roughly based on assay cross-reactivity.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Immunoenzymatic Assay)
Biomarkers
Erythropoietin
Analyte
LOINC Codes
- 15061-5 - EPO SerPl-aCnc
- 15061-5 - EPO SerPl-aCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.6 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Morning collection, from 7:30 a.m. to 12 p.m., is preferred due to diurnal variation. Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 14 days |